The Technical Analyst
GH Research PLC [GHRS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
GH Research PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.23% $10.50
America/New_York / 25 apr 2024 @ 10:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 546.30 mill |
| EPS: | -0.680 |
| P/E: | -15.44 |
| Earnings Date: | May 15, 2024 |
| SharesOutstanding: | 52.03 mill |
| Avg Daily Volume: | 0.127 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.44 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.63x |
| Company: PE -15.44 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.501 (-85.71%) $-9.00 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 9.78 - 11.22 ( +/- 6.87%) |
| ATR Model: 14 days |
Forecast:
12:29 - $10.65
Live Trading Signals (every 1 min)
Forecast
1: 10:59 - $10.52
Forecast 2: 11:49 - $10.58
Forecast 3: 12:29 - $10.65
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.50 (-5.23% ) |
| Volume | 0.0118 mill |
| Avg. Vol. | 0.127 mill |
| % of Avg. Vol | 9.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GHRS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GHRS
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Latest Press Releases
2024-02-29 07:00:00 - Press Release
Gh Research Reports Full Year 2023 Financial Results And Provides Business Updates
Dublin, ireland, feb. 29, 2024 (globe newswire) -- gh research plc (nasdaq: ghrs), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended december 31, 2023, and provided updates on its business.
2024-01-18 16:30:00 - Press Release
Gh Research Announces Grant Of European Patent Covering All Mebufotenin (5-meo-dmt) And Mebufotenin Salt Products For Use In The Treatment Of Major Depressive Disorder And Treatment-resistant Depression
Dublin, ireland, jan. 18, 2024 (globe newswire) -- gh research plc (nasdaq: ghrs), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the european patent office (epo) that it has been granted a patent with claims directed to mebufotenin (5-meo-dmt) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (mdd) and treatment-resistant forms of mdd, such as treatment-resistant depression (trd).
2023-11-09 16:45:00 - Press Release
Gh Research Reports Third Quarter Financial Results And Provides Business Updates
Dublin, ireland, nov. 09, 2023 (globe newswire) -- gh research plc (nasdaq: ghrs), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended september 30, 2023, and provided business updates.
2023-09-29 16:45:00 - Press Release
Gh Research Provides Updates And Guidance On Its Clinical Development Program For Gh001 In Treatment-resistant Depression
Dublin, ireland, sept. 29, 2023 (globe newswire) -- gh research plc (nasdaq: ghrs), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for gh001, its proprietary inhalable mebufotenin (5-meo-dmt) product candidate, in treatment-resistant depression (trd).
2023-08-23 07:00:00 - Press Release
Gh Research Reports Second Quarter 2023 Financial Results And Provides Business Updates
Dublin, ireland, aug. 23, 2023 (globe newswire) -- gh research plc (nasdaq: ghrs), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended june 30, 2023 and provided business updates.
Latest News
2024-03-05 10:55:26 - Zacks Investment Research
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2023-10-25 08:16:26 - Zacks Investment Research
New Strong Buy Stocks for October 25th
RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.
2023-06-29 08:00:53 - InvestorPlace
The 3 Best Psychedelic Stocks to Buy Now
Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly become a hot topic in the mental health space.
2023-02-05 14:30:41 - InvestorPlace
The 7 Most Promising Psychedelic Stocks to Buy in February
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
2023-01-15 11:45:00 - Seeking Alpha
Psychedelic Sunday: Competitive Strategies
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
2022-11-21 12:22:52 - InvestorPlace
7 Short-Squeeze Stocks for Bold Contrarians to Consider
Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.
2022-10-24 09:02:11 - Zacks Investment Research
New Strong Buy Stocks for October 24th
BXRX, WOLF, GHRS, RKDA and BHR have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2022.
2022-09-14 11:13:08 - Zacks Investment Research
Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?
The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2022-08-30 15:02:21 - InvestorPlace
7 Psychedelics Stocks to Buy for a Big Drug Boom
Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.
2022-01-19 16:31:52 - Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58